MLYS · Company research
Mineralys Therapeutics, Inc. Common Stock (MLYS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics (MLYS) Stock Dropped, So What Is Driving Attention Now? - Simply Wall Street | Mineralys Therapeutics (MLYS) Stock Dropped, So What Is Driving Attention Now? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 18, 2026 | neutral | 0 | 0.6 |
| An officer's proposed share sale at Mineralys Therapeutics (MLYS) lists a $78.1K market value. - Stock Titan | An officer's proposed share sale at Mineralys Therapeutics (MLYS) lists a $78.1K market value. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Mineralys Therapeutics CEO Jon Congleton sells $1.9m MLYS stock - Investing.com | Mineralys Therapeutics CEO Jon Congleton sells $1.9m MLYS stock Investing.com | View source ↗ | Investing.com | Oct 13, 2026 | neutral | 0 | 0.6 |
| Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain? - Yahoo Finance | Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Mineralys Therapeutics, Inc. (MLYS) Stock Price, News, Quote & History - Yahoo! Finance Canada | Mineralys Therapeutics, Inc. (MLYS) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 | Mineralys Therapeutics presented new clinical trial data for lorundrostat, its investigational aldosterone synthase inhibitor for treating difficult-to-treat hypertension. The Launch-HTN trial showed 46% of participants achieved AHA/ACC guideline systolic blood pressure targets (<130 mmHg) at 12 weeks, with over two-thirds achieving ≥10 mmHg reduction. The Explore-OSA trial demonstrated clinically meaningful morning blood pressure reductions in obstructive sleep apnea patients with no adverse effects on sleep apnea indices. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 | Mineralys Therapeutics presented new clinical trial data for lorundrostat, its investigational aldosterone synthase inhibitor for treating difficult-to-treat hypertension. The Launch-HTN trial showed 46% of participants achieved AHA/ACC guideline systolic blood pressure targets (<130 mmHg) at 12 weeks, with over two-thirds achieving ≥10 mmHg reduction. The Explore-OSA trial demonstrated clinically meaningful morning blood pressure reductions in obstructive sleep apnea patients with no adverse effects on sleep apnea indices. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| In a trial, 46% of people with hard-to-treat high blood pressure reached the recommended level in 12 weeks. - Stock Titan | In a trial, 46% of people with hard-to-treat high blood pressure reached the recommended level in 12 weeks. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 | Mineralys Therapeutics announced that new data from the Launch-HTN Phase 3 clinical trial of lorundrostat, an investigational aldosterone synthase inhibitor, will be presented at the American Society of Nephrology Kidney Week 2026. The presentation will focus on blood pressure and albuminuria reduction in chronic kidney disease patients. Lorundrostat is being developed to treat uncontrolled and resistant hypertension, with the company having completed six late-stage clinical trials demonstrating efficacy and safety. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| A sleep apnea trial of a blood pressure drug will be presented at a heart meeting. - Stock Titan | A sleep apnea trial of a blood pressure drug will be presented at a heart meeting. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Two new hires at Mineralys receive options on 46,430 shares and stock awards tied to 34,823 shares. - Stock Titan | Two new hires at Mineralys receive options on 46,430 shares and stock awards tied to 34,823 shares. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data - Yahoo Finance | Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data Yahoo Finance | View source ↗ | Yahoo Finance | Sep 28, 2026 | neutral | 0 | 0.6 |
| A Sept. 30 fireside chat with Mineralys management will stream live at noon ET. - Stock Titan | A Sept. 30 fireside chat with Mineralys management will stream live at noon ET. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Long-term results for a blood pressure drug will be presented at an American Heart Association meeting - Stock Titan | Long-term results for a blood pressure drug will be presented at an American Heart Association meeting Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda - Stock Titan | Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda Stock Titan | View source ↗ | Stock Titan | Aug 26, 2026 | neutral | 0 | 0.6 |
| Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View - Yahoo Finance | Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View Yahoo Finance | View source ↗ | Yahoo Finance | Aug 5, 2026 | neutral | 0 | 0.6 |
| A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger - Yahoo Finance | A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger Yahoo Finance | View source ↗ | Yahoo Finance | Jul 3, 2026 | neutral | 0 | 0.6 |
| MLYS Forecast — Price Target — Prediction for 2027 - TradingView | MLYS Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| $MLYS stock is down 13% today. Here's what we see in our data. - Quiver Quantitative | $MLYS stock is down 13% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 3, 2026 | neutral | 0 | 0.6 |
| Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now? - Yahoo Finance | Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now? Yahoo Finance | View source ↗ | Yahoo Finance | May 3, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.